Home >> News >> Business >> Peptide Therapeutics Market Is Expected To Reach USD 45,542.8 Mn By 2024

Peptide Therapeutics Market Is Expected To Reach USD 45,542.8 Mn By 2024

The latest market report published by Credence Research, Inc. “Global Peptide Therapeutics Market – Growth, Share, Opportunities, Pipeline Analysis, Competitive Analysis, and Forecast, 2016 – 2024,” the peptide therapeutics market was valued at USD 19,475.8 Mn in 2015, and is expected to reach USD 45,542.8 Mn by 2024, expanding at a CAGR of 9.8% from 2016 to 2024.

The purpose of the report is to illustrate the state of the market of Sterile Injectables, to present actual information about the volumes of production, exports, imports, consumption and the state of the market, the changes that took place in 2017, and also, to build a forecast for the growth of the industry in the medium term until 2026.

Browse here for full report: https://www.credenceresearch.com/report/peptide-therapeutics-market

Market Insights

Peptide therapeutics were observed as one of the most attractive and preferred options in recombinant medicine. The advantages such as low toxicity, high specificity, and much lower molecular weight makes it easy to set up dosage plans for patients. However, therapeutic peptides were introduced into the market couple of decades back, its market share and growth has significantly increased in past five or six years. The key factors assisting the global peptide therapeutics market are rising healthcare expenditure along with increasing importance of healthcare sector in developing countries. The main disease indications that are driving the demand for peptide therapeutics are cancer, metabolic disorders, and central nervous systems. Application of peptide therapeutics in oncology treatment is increasing mainly due to high mortality rate and moderately due to broader focus on emerging alternatives therapies to chemotherapy. The key application of peptide therapeutics is into oncology mainly used for treating prostrate, pancreatic, ovarian, and breast cancer. During preclinical stages efficacy testing of peptides in oncology treatment especially focusing on its property of being antagonists or agonists to specific receptors is tested.

In 2015, cancer segment accounted of the major market share due to rising prevalence of cancers coupled with high disease diagnosis rate, rising public awareness associated with the peptide therapeutics and developing overall healthcare infrastructure and supportive government policies. In 2015, solid phase peptide synthesis accounted for the largest market share due to introduction of novel products equipped with SPPS especially focusing on oral route of drug delivery. Some of the examples such as initially Unigene and then Enteris Biopharma developed a technology named Peptelligence which is based on an enteric-coated tablet, whose core formulation comprises, along with peptide, an organic acid enzyme inhibitor and permeation enhancer which is claimed to help penetrate the mucus layer. North America was observed as the largest market in peptide therapeutics industry due to factors such as high awareness associated with therapeutic treatment developments in public, high acceptance for novel products and technologies from patients and medical practitioners, and high healthcare costs.

According to market experts, in the near future peptide therapeutics is expected to be a huge breakthrough for both patients and drug manufacturing companies. In manufacturing and development of non-invasive delivery technologies, cost optimization is expected to generate significant revenue growth and better treatment outcomes for the patients.

Why was the report written?

This report is the result of an extensive survey drawn from Credence Research’s exclusive panel of leading global market industry executives; it provides data and analysis on buyer investment, acquisition, and developments within the global market research. It includes key topics such as global Sterile Injectables buyer expenditure and procurement behaviors and strategies and recognizes the threats and possibilities within the industry, economic outlook trends, and business confidence within global industry executives. Most secondary research reports are based on general industry drivers and do not understand the industry executives’ attitude and changing behaviors, creating a gap in presenting the business outlook of the industry; in an effort to bridge this gap, Credence Research created this primary research-based report by gathering the opinions of multiple stakeholders in the value chain of the global industry.

What is the current market landscape and what is changing?

Executives from the global industry anticipate an increase in levels of consolidation, with 55% of respondents projecting an increase in merger and acquisition (M&A) activities in 2017.

The report on the market of Peptide Therapeutics contains:

Analysis and forecast of Sterile Injectables market dynamics;

Analysis of domestic production, market shares of the main market players;

Analysis of exports and imports;

Analysis of factors, leading the development of the Sterile Injectables market;

Assessment and forecast of Sterile Injectables market development;

Financial and business profiles of the leading companies in the Sterile Injectables industry.

Scope

– Up to date working Sterile Injectables data by major regions in the world, the forecast of planned capacity additions by 2026

– The annual breakdown of capital expenditure spending on proposed Sterile Injectables for the period 2018 to 2026

– Planned Sterile Injectables additions and capital expenditure spending by key countries and companies across the world

– Planned capital expenditure spending on new Sterile Injectables projects by region, key countries, and companies

– Details of major planned Sterile Injectables projects in the world up to 2026

Also you can request us for sample in pdf with more details and graph: https://www.credenceresearch.com/sample-request/58361

About Us

Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.

Contact Us:

Credence Research Inc.

105 N 1st ST #429

SAN JOSE

CA 95103

United States

Toll Free (US/CANADA): +1-800-361-8290

Web: https://www.credenceresearch.com

Leave a Reply

Your email address will not be published. Required fields are marked *